Ucb S.A. · EURONEXT:UCB
Ucb — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
10 slides from Ucb's conference presentation, Jan 9, 2024
Slide 1: UCB: Five Growth Drivers For a Decade+
UCB: Five Growth Drivers For a Decade+ Jean-Christophe Tellier, CEO 42nd Annual J.P. Morgan Healthcare Conference January 9th, 2024
Slide 2: Disclaimer & Safe harbor
Disclaimer & Safe harbor This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking stat
Slide 3: UCB Patient Value Strategy
UCB Patient Value Strategy Sustained company growth – superior shareholder value Creating Value For Patients Our ambition is to be the patient-preferred biopharma leader, creating patient value for specific populations through unique outcomes, the best Proprietary and Confidential Property of UCB ex
Slide 4: The Coming Period of Growth is Built on a Solid Foundation
The Coming Period of Growth is Built on a Solid Foundation 2023 HY Net Sales € 2 378mn1 Peak sales guidance of € >2bn achieved ahead of time (-12%; -14% CER) Epilepsy Volume growth ahead of anti-TNF market thanks to € 957mn CIMZIA® differentiation (-33%; -32% CER) No biosimilar competition expected
Slide 5: Five Growth Drivers for a Decade+
Five Growth Drivers for a Decade+ Proprietary and Confidential Property of UCB Coverage WW Coverage WW* Coverage WW Disease area Postmenopausal Osteoporosis (PMO) Disease area PSO, PsA, r- & nr-axSPA, HS Disease area DS, LGS Prevalence 1/3 women >50yr1 Prevalence PSO: ~ 3%-5% HS: ~1% Prevalence DS:
Slide 6: Approval Trajectory of Growth Drivers
Five Growth Drivers for a Decade+ A P P R O V A L TR A J E C T O R Y PSO, US and PsA & r- & nr-axSpA, ex-US Proprietary and Confidential Property of UCB PSO, ex-US 2019 2021 2022 2023 • First new osteoporosis approval • First and only IL-17A and IL-17F • Unique and dual mode of gMG leadership ambiti
Slide 7: Innovative Clinical Pipeline, Focus on Areas of Expertise
Innovative Clinical Pipeline, Focus on Areas of Expertise News flow for all trials in 2024 expected PHASE 1 PHASE 2 PHASE 3 TOPLINE RESULTS TIMING KEY FACTS rozanolixizumab (FcRn inhibitor) Targeted FcRn inhibition in a population that has a severe MOG-antibody disease H2 2024 brain inflammation and
Slide 8: 2025 Guidance is Next Milestone After Reaching Inflection Point at HY23
2025 Guidance is Next Milestone After Reaching Inflection Point at HY23 Financial Guidance 2025: • At least € 6bn top line • Low- to mid-thirties adj. EBITDA margin • Improved ESG rating performance Proprietary and Confidential Property of UCB 2025 How We Get There… €5.8bn >€6bn GUIDANCE 2025 €5.5bn
Slide 9: Entering a Growth Phase With for a Decade+
Entering a Growth Phase With Five Growth Drivers for a Decade+ UCB’s Building Blocks for a Decade+ Growth: Pioneering Proprietary and Confidential Property of UCB Deliver differentiated solutions with unique outcomes for patients Innovation • Solid foundation of current core strategic products Lever
Slide 10: Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB
UCB — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix